Ad-hoc | 23 April 2009 15:15
STRATEC Biomedical Systems AG / Acquisition
Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
----------------------------------------------------------------------
STRATEC acquires Invitek
Birkenfeld, April 23, 2009
The STRATEC Group, Birkenfeld, Germany (Frankfurt: SBS; Prime Standard),
has today acquired one hundred percent of the shares in the privately owned
company Invitek Gesellschaft für Biotechnik & Biodesign mbH, Berlin,
Germany. In terms of the STRATEC Group's corporate structure, the newly
acquired company will be incorporated into the STRATEC group under the
wholly-owned subsidiary Robion AG, Neuhausen/Rheinfall, Switzerland.
STRATEC is financing the acquisition with available funds and with treasury
stock from the Company's holdings. The purchase price (net of cash assets
and liabilities) consists of a cash amount of around Euro 2.1 million and
around 70.000 treasury stocks in STRATEC Biomedical Systems AG, which may
only be resold upon specified conditions being met. In addition, a variable
purchase price component amounting to a maximum of Euro 0.35 million by the
end of 2009 has been agreed and is dependent on the achievement of
performance and development targets.
The additional sales and earnings generated by Invitek will change the
consolidated figures forecast for 2009 within the corridor published by
STRATEC in its financial guidance for 2009. As a result, no amendments are
required to that guidance.
---------------------------------------------------------------------------
Information and Explaination of the Issuer to this News:
About STRATEC
STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs
and manufactures fully automated systems for its partners in the fields of
clinical diagnostics and biotechnology. These partners market such systems,
in general together with their own reagents, to laboratories, blood banks
and research institutes around the world. The company develops its products
on the basis of its own patented technologies. Shares in the company (ISIN:
DE0007289001) are traded in the Prime Standard segment of the Frankfurt
Stock Exchange.
The STRATEC Group consists of the publicly listed parent company STRATEC
Biomedical Systems AG and of subsidiaries and second-tier subsidiaries in
Germany, the USA, the UK, Switzerland and Romania.
Further information can be obtained from:
STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916 190
Fax: +49 7082 7916 999
E-mail: ir@stratec-biomedical.de
23.04.2009 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: STRATEC Biomedical Systems AG
Gewerbestraße 37
75217 Birkenfeld
Deutschland
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec-biomedical.de
Internet: www.stratec-biomedical.de
ISIN: DE0007289001
WKN: 728900
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Stuttgart, München, Düsseldorf
End of News DGAP News-Service
---------------------------------------------------------------------------